RCS - Hikma Pharmaceutical - Hikma expands nasal spray capabilities

Hikma PharmaceuticalsAnnouncement

09/08/2019 09:00

RNS Number : 4836I
Hikma Pharmaceuticals Plc
09 August 2019
 


London, 9 August 2019 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational pharmaceutical company, today announces that it has signed an asset purchase agreement with Insys Therapeutics Inc. (Insys) to acquire a complementary manufacturing platform and two pipeline products.
 
In June 2019, Insys filed petitions seeking relief under Chapter 11 of the US Bankruptcy Code. As part of this process, Insys initiated a court-supervised process to sell its assets. This process has now concluded with respect to certain assets, and Hikma has agreed to acquire unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products, naloxone 505(b)2 nasal spray and epinephrine 505(b)2 nasal spray.
 
Brian Hoffmann, President of Generics, stated, "Hikma is the largest supplier of generic nasal sprays in the US and we have been looking for ways to build upon our strong manufacturing platform and expand our product portfolio. This acquisition adds unit-dose nasal spray manufacturing equipment, as well as two complex products to our pipeline. This new technology expands our existing nasal spray capabilities, creating a comprehensive platform, which we can leverage for both internal and partnership programmes."
 
About naloxone
Naloxone is a medication used to block or reverse the effect of opioids. Narcan® is the only nasal form of naloxone on the market.  According to IQVIA, US sales of Narcan® were approximately $164 million in the 12 months ending June 2019. 
 
About epinephrine
Epinephrine is a medication used to treat a number of conditions, including anaphylaxis, cardiac arrest, and superficial bleeding. According to IQVIA, US sales of epinephrine auto-injectors were approximately $4.3 billion in the 12 months ending June 2019.  There are no currently approved nasal forms of epinephrine in the US.
-- ENDS -
 
 
Enquiries
Hikma Pharmaceuticals PLC



Susan Ringdal

EVP, Strategic Planning and Global Affairs


+44 (0)20 7399 2760/ +44 7776 477050




Lucinda Baker
Director, Investor Relations


+44 (0)20 7399 2765/ +44 7818 060211



 
FTI Consulting



Ben Atwell/Andrew Ward


+44 (0)20 3727 1000



 
 
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGUPPRUPBPGR